Piper Sandler maintains Replimune Group at Overweight, raises price target to $27 from $14

Piper Sandler kept its Overweight rating on Replimune Group and raised its price target to $27 from $14, suggesting a 23.3% upside from the Nov 13 close of $21.89.

Original reporting
Published Nov 16, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains Replimune Group at Overweight, raises price target to $27 from $14 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The price target hike could attract new buyers and support the stock price.

02

Market read

Analyst upgrade may provide a short-term catalyst for RPLM.

03

What to watch

Potential regulatory or clinical trial setbacks could temper upside.

Relevance 5/10Novelty 5/10Timing: today

Background

Piper Sandler's analyst report updates the valuation of Replimune Group.

Market effects

May lift sentiment in the biotech/oncology sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Target may be overly optimistic given limited data on product pipeline.

Key entities

  • Replimune Group

    Biotech firm focused on oncolytic virus therapies.

  • Piper Sandler

    Investment bank providing the rating upgrade.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.